In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Atlas Genetics Ready To Play Its Part In The POC Workflow Revolution

Executive Summary

Do it once, do it right and do it quick: when it comes to diagnostic testing, that suits patients and payer systems that are pursuing budget-sensitive, quality-driven health care solutions. It could also be the shorthand mission statement of POC diagnostics developer Atlas Genetics, which is developing a new IVD platform technology for infectious disease tests.

You may also be interested in...



Atlas Genetics Fundraising Pulls In New Chinese Investment

Atlas Genetics, a UK point-of-care molecular diagnostics developer, has raised $35m in Series D financing from an investor syndicate. The funding round attracted existing shareholders and new investment from Chinese in vitro diagnostic company Wondfo Biotech.

Atlas First In Market With 30-Minute POC Molecular Test For Chlamydia

Atlas Genetics is bringing to market the first point-of-care molecular diagnostic test for chlamydia that can deliver results in 30 minutes. The rapid turnaround time will hopefully reduce the number of patients who do not go back to retrieve their results and consequently not get the necessary treatment should they have the sexually transmitted infection (STI).

Novel Models Of Care Must Feature In Updated UK NHS Plan

COVID has necessitated a refresh of NHS England’s Long Term Plan, which must double down on concepts such as at-home, patient-empowered care and virtual wards, says the NHS Confederation.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel